文献速递慢性肾脏病

即时经皮GFR检测方法的准确性评估

Accuracy of Point-of-Care Transdermal GFR Methodology.
PubMed 文献 · Kidney Int Rep · 2026-01-22

本研究为多中心关键性临床试验,纳入182例肾功能正常至CKD 4期、覆盖全部6种Fitzpatrick皮肤类型的参与者,比较经皮GFR(tGFR)与血浆衍生指数化GFR(nGFR)的一致性。主要终点为tGFR值落在nGFR±30%范围内的百分比(P30),全队列P30达94%(95%CI:89%-97%),各CKD分层及皮肤类型亚组的P30均在2024年KDIGO指南确立的最佳范围内。

要点

  • 全队列tGFR的P30为94%(95%CI:89%-97%),优于文献报道的基于肌酐的eGFR方程。
  • GFR>60与<60 ml/min/1.73 m²亚组的P30分别为96%和92%。
  • FSS I-III型与IV-VI型皮肤亚组的P30分别为96%和90%,各亚组P30均在2024 KDIGO最佳范围内。

核心结论

  • tGFR的P30值高于当前文献报道的基于肌酐的eGFR方程。
  • 在CKD分层和FSS亚组中,观察到的所有P30值均处于2024年KDIGO指南确立的最佳范围内。

研究设计与样本

  • 多中心关键性临床研究,纳入182例eGFR正常至CKD 4期、覆盖全部6种Fitzpatrick皮肤类型的参与者。
  • 胸部传感器含发光二极管和光电检测器,静脉注射relmapirazin后进行经皮荧光检测。
  • 主要终点为tGFR值落在nGFR±30%范围内的百分比(P30)。

主要发现

  • 全队列P30为94%(95%CI:89%-97%)。
  • GFR>60 ml/min/1.73 m²参与者P30为96%,GFR<60 ml/min/1.73 m²参与者P30为92%。
  • FSS I-III型参与者P30为96%,FSS IV-VI型参与者P30为90%。

关键数值与推荐

  • 主要终点P30定义为tGFR值在nGFR±30%范围内的百分比。
  • 2024年KDIGO指南确立了P30的最佳范围,本研究中所有亚组P30值均处于该范围内。

临床怎么用

  • tGFR可在即时检测场景下评估临床相关范围的GFR,且适用于所有人类肤色。
  • tGFR可能作为基于肌酐的eGFR方程的替代方法,用于个体化GFR评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic kidney disease (CKD) is typically staged using population-derived empirical equations to estimate glomerular filtration rate (GFR) based on serum creatinine and/or cystatin C. However, these estimated GFR (eGFR) equations can be inaccurate for an individual patient. Although plasma-derived GFR using an exogenous agent is the preferred methodology, the requirement for multiple blood samples and laboratory analysis limits its practical clinical utility. We have shown that the fluorescent molecule, relmapirazin, is an exogenous GFR tracer agent and its transdermal fluorescence detection at the point-of-care can assess a clinically relevant range of GFR across all human skin colors. In the current study, transdermal GFR (tGFR) was compared with the plasma-derived indexed GFR (nGFR) in a multicenter pivotal clinical study. METHODS: We evaluated 182 participants with normal eGFR to CKD stage 4 across all 6 Fitzpatrick Skin Scale (FSS) types. A sensor attached to the chest contained a light emitting diode and photodetector for transdermal fluorescence detection following i.v. administration of relmapirazin. The primary end point was percentage of tGFR values within 30% of nGFR (P30). RESULTS: P30 of 94% (95% confidence interval [CI]: 89%-97%) was obtained for the entire cohort. P30 was 96% and 92% for participants with GFR > or < 60 ml/min per 1.73 m2, respectively. P30 of 96% was for participants with FSS I to III and 90% with IV to VI. CONCLUSION: The tGFR yielded a higher P30 value than creatinine-based eGFR equations reported in the current literature. For the cohort subsets of CKD strata and FSS, all P30 values observed were in the optimal range as established by the 2024 Kidney Disease: Improving Global Outcomes guideline.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Dorshow RB, Friedemann J, Ross-Jones J, et al. Accuracy of Point-of-Care Transdermal GFR Methodology. Kidney Int Rep. 2026. PMID: 41726007. doi:10.1016/j.ekir.2026.103797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。